KOD Stock Price, Kodiak Sciences Inc Quote, Chart

Market Summary

USD3.30-0.44

Market Closed

-11.76%

KOD Stock Price

View Fullscreen

KOD RSI Chart

KOD Valuation

Market Cap

173.4M

Price/Earnings (Trailing)

-0.74

Price/Free Cashflow

-0.99

KOD Price/Sales (Trailing)

KOD Profitability

Return on Equity

-96.5%

Return on Assets

-53.54%

Free Cashflow Yield

-101.38%

KOD Fundamentals

KOD Earnings

Earnings (TTM)

-232.8M

Earnings Growth (Yr)

39.19%

Earnings Growth (Qtr)

27.68%

Breaking Down KOD Revenue

Last 7 days

-8.6%

Last 30 days

-8.3%

Last 90 days

-39%

Trailing 12 Months

-38.2%

How does KOD drawdown profile look like?

KOD Financial Health

Current Ratio

10.12

KOD Investor Care

Shares Dilution (1Y)

0.34%

Diluted EPS (TTM)

-4.43

Tracking the Latest Insider Buys and Sells of Kodiak Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 16, 2023	ehrlich jason	sold	-20,841	9.23	-2,258	see remarks
Jun 16, 2023	borgeson john a.	sold	-25,373	9.23	-2,749	see remarks
Jun 15, 2023	borgeson john a.	acquired	-	-	5,494	see remarks
Jun 15, 2023	ehrlich jason	acquired	-	-	5,494	see remarks
Jun 14, 2023	ehrlich jason	sold	-10,663	9.42	-1,132	see remarks
Jun 14, 2023	borgeson john a.	sold	-13,640	9.42	-1,448	see remarks
Jun 11, 2023	ehrlich jason	acquired	-	-	2,900	see remarks
Jun 11, 2023	borgeson john a.	acquired	-	-	3,025	see remarks
Dec 30, 2022	perlroth victor	gifted	-	-	-60,000	chairman and ceo
Jun 17, 2022	ehrlich jason	sold	-16,019	7.02	-2,282	see remarks

Which funds bought or sold KOD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-38.69	22,462	391,576	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	925	17,153	-%
May 15, 2024	BARCLAYS PLC	reduced	-41.9	2,000	312,000	-%
May 15, 2024	Voya Investment Management LLC	reduced	-32.31	8,430	57,681	-%
May 15, 2024	LJI Wealth Management, LLC	reduced	-12.42	25,222	74,166	0.02%
May 15, 2024	TCG Crossover Management, LLC	added	235	3,919,460	4,734,000	0.37%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	added	23.88	3,476,200	6,516,200	1.81%
May 15, 2024	Engineers Gate Manager LP	sold off	-100	-67,756	-	-%
May 15, 2024	Newtyn Management, LLC	reduced	-43.54	-124,573	5,260,000	1.05%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	313	1,298,600	1,509,690	-%

Are Funds Buying or Selling KOD?

Are funds buying KOD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KOD

No. of Funds

Unveiling Kodiak Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perlroth victor	10.4%	5,758,427	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	4,032,822	SC 13G/A
Feb 14, 2023	perlroth victor	12.2%	6,691,321	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	0.9%	472,013	SC 13G/A
Feb 09, 2023	vanguard group inc	3.17%	1,657,156	SC 13G/A
Feb 03, 2023	blackrock inc.	8.2%	4,287,809	SC 13G
Jun 06, 2022	baker bros. advisors lp	33.4%	17,353,846	SC 13D/A
May 18, 2022	baker bros. advisors lp	31.6%	16,431,091	SC 13D/A
Mar 10, 2022	wellington management group llp	3.20%	1,654,396	SC 13G/A
Mar 10, 2022	price t rowe associates inc /md/	5.1%	2,685,747	SC 13G/A

Recent SEC filings of Kodiak Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 23, 2024	DEFA14A	DEFA14A
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	ARS	ARS
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Kodiak Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Kodiak Sciences Inc News

Latest updates

Kodiak Sciences Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.3%	435	479	548	590	640	667	724	782	850	904	958	998	1,033	1,067	481	429	443	359	69.00	78.00	87.00
Current Assets	-13.1%	252	289	351	387	431	486	545	604	682	735	806	884	932	972	382	419	425	339	61.00	70.00	83.00
Cash Equivalents	-13.9%	246	286	346	379	317	190	178	173	672	732	799	881	920	944	292	270	226	212	37.00	45.00	57.00
Net PPE	-3.9%	116	120	125	130	135	56.00	56.00	55.00	49.00	41.00	23.00	9.00	7.00	5.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-9.4%	194	214	245	251	248	230	244	251	253	241	232	218	211	207	199	120	115	14.00	9.00	8.00	7.00
Current Liabilities	-40.4%	25.00	42.00	71.00	74.00	69.00	52.00	66.00	70.00	76.00	65.00	54.00	41.00	35.00	31.00	23.00	19.00	14.00	12.00	7.00	6.00	5.00
Shareholder's Equity	-9.3%	241	266	302	338	393	436	480	531	597	663	726	779	822	861	282	309	328	345	60.00	70.00	80.00
Retained Earnings	-3.7%	-1,195	-1,152	-1,093	-1,043	-962	-892	-821	-744	-653	-558	-465	-397	-341	-291	-244	-208	-182	-158	-142	-130	-118
Additional Paid-In Capital	1.3%	1,437	1,418	1,395	1,381	1,355	1,330	1,304	1,277	1,251	1,222	1,191	1,177	1,163	1,152	526	517	510	503	202	200	199
Shares Outstanding	0.0%	53.00	53.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	222	-	-	-	243	-	-	-	3,100	-	-	-	1,600	-	-	-	274	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-22.8%	-39,600	-32,239	-32,764	-41,959	-47,221	-55,075	-53,087	-55,137	-43,160	-59,035	-51,949	-36,661	-34,625	-27,019	-24,572	-13,905	-17,932	-11,293	-7,696	-12,950	-7,207
Share Based Compensation	-19.4%	18,409	22,829	13,946	25,801	25,980	25,778	26,182	25,978	28,095	27,996	12,377	11,087	9,925	9,455	8,241	6,890	6,082	1,936	1,773	1,244	1,157
Cashflow From Investing	99.4%	-166	-27,798	-226	103,844	173,406	66,998	58,730	-443,952	-18,289	-10,859	-31,705	-5,452	9,218	58,858	56,392	56,781	-67,197	-113,283	-523	680	-23,872
Cashflow From Financing	130.6%	38.00	-124	-12.00	170	-3.00	97.00	78.00	54.00	1,666	2,157	2,031	2,522	1,472	616,281	804	504	99,788	299,340	285	15.00	47.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KOD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 29,931	$ 56,520
General and administrative	16,124	18,095
Total operating expenses	46,055	74,615
Loss from operations	(46,055)	(74,615)
Interest income	3,353	3,617
Interest expense	0	(4)
Other income (expense), net	(337)	222
Net loss	$ (43,039)	$ (70,780)
Net loss per common share, basic	$ (0.82)	$ (1.35)
Net loss per common share, diluted	$ (0.82)	$ (1.35)
Weighted-average shares of common stock outstanding used in computing net loss per common share, Basic	52,510,460	52,337,603
Weighted-average shares of common stock outstanding used in computing net loss per common share, Diluted	52,510,460	52,337,603
Other comprehensive income (loss)
Change in unrealized gains (losses) related to available-for-sale debt securities, net of tax	$ 0	$ 1,211
Total other comprehensive income (loss)	0	1,211
Comprehensive loss	$ (43,039)	$ (69,569)

KOD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 245,919	$ 285,507
Prepaid expenses and other current assets	5,593	3,802
Total current assets	251,512	289,309
Restricted cash	6,184	6,324
Property and equipment, net	115,801	120,482
Operating lease right-of-use asset	52,561	54,541
Other assets	8,701	8,716
Total assets	434,759	479,372
Current liabilities:
Accounts payable	2,485	13,608
Accrued and other current liabilities	12,765	18,351
Operating lease liability	9,605	9,770
Total current liabilities	24,855	41,729
Operating lease liability, net of current portion	68,715	71,862
Liability related to sale of future royalties	100,000	100,000
Total liabilities	193,570	213,591
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized: 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.0001 par value, 490,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,523,447 and 52,508,602 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	1,436,754	1,418,307
Accumulated deficit	(1,195,570)	(1,152,531)
Total stockholders’ equity	241,189	265,781
Total liabilities and stockholders’ equity	$ 434,759	$ 479,372

About Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naÃƒÂ¯ve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

CEO	Dr. Victor Perlroth M.D.
WEBSITE	https://kodiak.com
INDUSTRY	Biotechnology
EMPLOYEES	118

Kodiak Sciences Inc Frequently Asked Questions

What is the ticker symbol for Kodiak Sciences Inc? What does KOD stand for in stocks?

KOD is the stock ticker symbol of Kodiak Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kodiak Sciences Inc (KOD)?

As of Fri May 17 2024, market cap of Kodiak Sciences Inc is 173.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KOD stock?

You can check KOD's fair value in chart for subscribers.

What is the fair value of KOD stock?

You can check KOD's fair value in chart for subscribers. The fair value of Kodiak Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kodiak Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KOD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kodiak Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether KOD is over valued or under valued. Whether Kodiak Sciences Inc is cheap or expensive depends on the assumptions which impact Kodiak Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KOD.